Market accessCompany release

Medicare begins paying $1,938.01 per EsoGuard test as Lucid reports record October volume

🇺🇸 Lucid Diagnostics Inc. (LUCD) · Thu 12 Nov 2026

Lucid Diagnostics says Medicare is paying EsoGuard claims at the full fee schedule rate, with coverage granted case by case while a wider MolDX reconsideration remains pending.

Lucid Diagnostics said in its third-quarter 2026 update, issued on 12 November, that Medicare has started paying claims for its EsoGuard esophageal DNA test. Payment is at the Clinical Laboratory Fee Schedule rate of $1,938.01 per test.

According to the company, coverage is being granted claim by claim through Novitas, the Medicare contractor. This route is separate from the reconsideration of the MolDX Local Coverage Determination, which is still pending. The update does not indicate when that reconsideration might conclude.

On the commercial side, Lucid recorded $1.2 million of revenue in the third quarter from 2,871 tests. It reported more than 1,800 tests in October alone, which it describes as a record month.

After the quarter closed, the company completed a $15.0 million Series C preferred stock financing. No further terms of the financing were provided in the material available.

What it means for your team

  • Market-access teams should note that Medicare payment here is being secured claim by claim rather than through a settled Local Coverage Determination, so reimbursement may remain less predictable until the MolDX reconsideration is resolved.
  • Diagnostics developers can see that a published fee schedule rate does not by itself guarantee payment; individual coverage decisions by the contractor still matter.
  • Payers and analysts tracking test uptake may watch whether October's volume holds once claim-by-claim coverage has been in place for longer.

Company's press release (SEC filing): Lucid Diagnostics Inc. ↗

Article written by VigiEye from the official source (Lucid Diagnostics Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Market access All →